GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-12-26| Trials & Approvals

Roche’s Lunsumio Lands FDA Approval for Pretreated Follicular Lymphoma

by Reed Slater
Share To

After gaining European approval in June, Roche’s bispecific antibody, Lunsumio, snagged another win with accelerated approval from the FDA to treat relapsed or refractory follicular lymphoma. With its new status, the drug has the opportunity to compete with its CAR-T competitors like Yescarta and Kymriah.

Promising Clinical Data Supporting the FDA’s Decision

The FDA based its approval on data from the Phase 2 GO29781 study, which enrolled 90 participants with relapsed or refractory follicular lymphoma. The disease is the most common slow-growing form of non-Hodgkin lymphoma. Follicular lymphoma can respond to treatment but often returns, prompting another form of treatment. As a patient undergoes more and more treatments, attaining remission typically becomes more difficult. 

Because Roche applied for accelerated approval, the GO29781 study used surrogate endpoints like overall response rate to measure Lunsumio’s success in treating follicular lymphoma. About 80% of Lunsumio patients throughout the trial experienced an objective response. Roche characterized an objective response as a combination of complete and partial response rates. Among those who responded to Lunsumio, the median response duration lasted 22.8 months. 

Roche designed Lunsumio as a CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on B-cell surfaces and CD3 on T-cell surfaces. This process allows existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins. 

Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development, said, “Lunsumio represents our first approved T-cell engaging bispecific antibody and builds on our legacy of more than 20 years of innovation in blood cancer.”

Related Article: Moderna’s Personalized Cancer Therapy: The New Transformative Approach to Oncology

Sizing Up the CAR-T Competition

Some other new and promising developments in follicular lymphoma treatments include autologous CAR-T cell therapies like Kite’s Yescarta and Novartis’ Kymriah. Lunsumio is now in direct competition with these revolutionary therapies. 

Lunsumio has some benefits that CAR-T cell therapies can not compete within their current state. For example, some patients can receive Lunsumio in an outpatient setting if they meet certain criteria. This could cut down costs on healthcare and make it more convenient for patients. The intravenous infusion is also administered for a fixed duration, allowing time off therapy.

Despite CAR-T cell therapies’ impressive track record so far, they are expensive and time-consuming. Kymriah can cost $475,000 per treatment regimen, and Yescarta around $373,000. Patients also have to undergo tests and have samples taken for scientists to manufacture the personalized therapy. 

Roche has yet to confirm how much Lunsumio will cost, but the off-the-shelf antibody will likely be less than autologous CAR-T cell therapies. The company has high hopes for the drug in the U.S. market. Biogen will also reap some of those rewards after laying down $30 million in February for low single-digit royalties from sales in America. 

The most recent accelerated approval for Roche’s Lunsumio is an exciting development that will add another treatment option for patients with relapsed or refractory follicular lymphoma. The company said it would roll the drug out to the market in the coming weeks, and 2023 will see whether or not it holds a flame to its CAR-T cell competitors. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Roche’s STI Test Clears FDA Potentially Becoming A Game-Changer for Fast, Accurate Diagnosis
2025-01-23
China’s Innovent Biologics Secures USD $1 Billion ADC Oncology Licensing Agreement with Roche
2025-01-06
The Boldest Business Matchmaking of 2024: A Look at the Top M&A Activity
2025-01-02
LATEST
Lilly’s Omvoh’s Two-Year Journey Confirms Lasting Impact on Crohn’s Disease Treatment
2025-02-08
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
First-of-its-Kind Diagnostic Aid Uses a Single Hair Strand to Detect Autism Risk in Babies
2025-02-06
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech
2025-02-06
Johnson & Johnson Under Fire Again as Legal Action Over Alleged Talc-Cancer Link Moves to the UK
2025-02-05
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top